ABBV
Another way to sell the glow
AbbVie’s Allergan Aesthetics unit is heading to the 2026 Science of Skin Summit with fresh clinical data in hand. The studies look at targeted skincare regimens, both by themselves and paired with DiamondGlow dermabrasion, in people taking medical weight loss medications like GLP-1 receptor agonists.
Why this matters
This isn’t the kind of headline that makes a stock jump 20% before lunch. But it does show AbbVie is still trying to keep its aesthetics business relevant in a weird new world where GLP-1 drugs are changing how people think about weight loss, skin quality, and the whole post-weight-loss beauty economy.
If the company can convince consumers and providers that it has a useful solution for skin issues tied to rapid weight loss, that’s a nice little tailwind for a franchise that lives and dies on staying trendy.
The bigger picture
Aesthetics is basically the fashion industry with syringes: trends move fast, and what’s hot one year can look tired the next. AbbVie’s pitch here is that skincare plus dermabrasion can help fill a new need created by the GLP-1 boom.
Big picture: this is a modest but real reminder that AbbVie’s growth story isn’t just about drugs. Sometimes it’s about helping people look in the mirror after the scale starts cooperating.